Literature DB >> 22343625

Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Kwang H Ahn1, Mariam M Mahmoud, Debra A Kendall.   

Abstract

The cannabinoid receptor 1 (CB1), a member of the class A G protein-coupled receptor family, is expressed in brain tissue where agonist stimulation primarily activates the pertussis toxin-sensitive inhibitory G protein (G(i)). Ligands such as CP55940 ((1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3- hydroxypropyl)cyclohexan-1-ol) and Δ(9)-tetrahydrocannabinol are orthosteric agonists for the receptor, bind the conventional binding pocket, and trigger G(i)-mediated effects including inhibition of adenylate cyclase. ORG27569 (5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)ethyl]amide) has been identified as an allosteric modulator that displays positive cooperativity for CP55940 binding to CB1 yet acts as an antagonist of G protein coupling. To examine this apparent conundrum, we used the wild-type CB1 and two mutants, T210A and T210I (D'Antona, A. M., Ahn, K. H., and Kendall, D. A. (2006) Biochemistry 45, 5606-5617), which collectively cover a spectrum of receptor states from inactive to partially active to more fully constitutively active. Using these receptors, we demonstrated that ORG27569 induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased inverse agonist affinity consistent with an active conformation. Also consistent with this conformation, the impact of ORG27569 binding was most dramatic on the inactive T210A receptor and less pronounced on the already active T210I receptor. Although ORG27569 antagonized CP55940-induced guanosine 5'-3-O-(thio)triphosphate binding, which is indicative of G protein coupling inhibition in a concentration-dependent manner, the ORG27569-induced conformational change of the CB1 receptor led to cellular internalization and downstream activation of ERK signaling, providing the first case of allosteric ligand-biased signaling via CB1. ORG27569-induced ERK phosphorylation persisted even after pertussis toxin treatment to abrogate G(i) and occurs in HEK293 and neuronal cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343625      PMCID: PMC3320953          DOI: 10.1074/jbc.M111.316463

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

Review 2.  Multiple switches in G protein-coupled receptor activation.

Authors:  Shivani Ahuja; Steven O Smith
Journal:  Trends Pharmacol Sci       Date:  2009-09-03       Impact factor: 14.819

3.  The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase.

Authors:  D Rueda; I Galve-Roperh; A Haro; M Guzmán
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

4.  Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.

Authors:  G Cristina Brailoiu; Tudor I Oprea; Pingwei Zhao; Mary E Abood; Eugen Brailoiu
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

Review 5.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 6.  Cellular signal transduction by anandamide and 2-arachidonoylglycerol.

Authors:  A C Howlett; S Mukhopadhyay
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

7.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

8.  Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor.

Authors:  Nuska Tschammer; Stefan Bollinger; Terry Kenakin; Peter Gmeiner
Journal:  Mol Pharmacol       Date:  2010-12-16       Impact factor: 4.436

9.  Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus.

Authors:  P Derkinderen; C Ledent; M Parmentier; J A Girault
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

10.  Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism.

Authors:  Tanya L Daigle; Mary Lee Kwok; Ken Mackie
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

View more
  72 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.

Authors:  Aurélie Borrull; Bertrand Allard; Anne Wijkhuisen; Amaury Herbet; Patricia Lamourette; Wided Birouk; Denis Leiber; Zahra Tanfin; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud; Philippe Robin
Journal:  MAbs       Date:  2016-07-08       Impact factor: 5.857

Review 3.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

4.  Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

5.  Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.

Authors:  Jonathan F Fay; David L Farrens
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 6.  Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.

Authors:  Zhiwei Feng; Guanxing Hu; Shifan Ma; Xiang-Qun Xie
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

Review 7.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

Review 8.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

9.  Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gαiβγ: identification of key CB1 contacts with the C-terminal helix α5 of Gαi.

Authors:  Joong-Youn Shim; Kwang H Ahn; Debra A Kendall
Journal:  J Biol Chem       Date:  2013-10-03       Impact factor: 5.157

10.  Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor.

Authors:  M Cecilia Ortiz-Capisano; Mahendranath Reddy; Mariela Mendez; Jeffrey L Garvin; William H Beierwaltes
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.